THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION If you are in any doubt as to what action you should take, you are recommended to seek your own financial advice from your stockbroker or other independent

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR

If you are in any doubt as to what action you

should take, you are recommended to seek your own financial advice from your stockbroker or other independent adviser authorized under

the Financial Services and Markets Act 2000 (as amended).

If you have recently sold or transferred all

of your shares in AKARI THERAPEUTICS, PLC, please forward this document, together with the accompanying documents, as soon as possible

either to the purchaser or transferee or to the person who arranged the sale or transfer so they can pass these documents to the person

who now holds the shares.

AKARI THERAPEUTICS, PLC

(Registered in England & Wales, No. 05252842)

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

TO BE HELD ON JUNE 30, 2022

Dear Shareholders of Akari Therapeutics, Plc:

Although there are currently

no UK Government restrictions on travel or public gatherings in connection with Covid-19, it remains possible that such restrictions or

other impediments may make it difficult or impossible for shareholders, or their proxies other than the chairman of the Meeting, to attend

the Meeting in person. Shareholders should inform themselves of and comply with all laws and UK Government guidance in force at the date

of the Meeting. Moreover, for their own safety and that of our staff and the public, we encourage shareholders not to attend the Meeting

in person unless they have a good reason for doing so. We therefore strongly encourage you to vote on all resolutions as soon as possible

by appointing the chairman of the Meeting as your proxy (or, in the case of beneficial owners who hold their shares indirectly, by submitting

appropriate proxy voting instructions) as described in the Proxy Statement below.

Notice is hereby given of

the annual general meeting (the "Meeting") of the shareholders of Akari Therapeutics, Plc, ("Akari"

or the "Company"), to be held at 2.30 p.m., local time, on June 30, 2022, at 75/76 Wimpole Street, London, W1G 9RT

for the purpose of considering and, if thought fit, passing the following resolutions, which will all be proposed as ordinary resolutions.

Ordinary Resolutions

Pursuant to Regulation 41

of the Uncertificated Securities Regulations 2001, as amended, the Company specifies that entitlement to attend and vote at the Meeting,

and the number of votes which may be cast at the Meeting, will be determined by reference to the Company's register of members at

6.30 p.m. (London time) on June 28, 2022 or, if the Meeting is adjourned, at 6.30 p.m. (London time) two working days before

the time of the adjourned Meeting. In each case, changes to the register of members after such time will be disregarded. The accompanying

Proxy Statement more fully describes the details of the business to be conducted at the Meeting. After careful consideration, our Board

of Directors has unanimously approved the proposals and recommends that you vote FOR each proposal described in the accompanying Proxy

The Company's principal

executive offices are located at 75/76 Wimpole Street, London W1G 9RT. The registered office of Akari Therapeutics, Plc is at Highdown

House, Yeoman Way, Worthing, West Sussex, BN99 3HH, United Kingdom. Except as set out in this Notice, any communication with the Company

in relation to the Meeting, should be sent to the Company's registrars, SLC Registrars, PO Box 5222, Lancing, BN99 9FG, United Kingdom.

No other means of communication will be accepted. In particular, you may not use any electronic address provided within this notice or

in any related documents (including the annual report and accounts for the year ended December 31, 2021 and the proxy form) to communicate

with the Company except as expressly permitted.

You are reminded that you

can update your preferences for communications by Akari at any time through SLC Registrars' "ShareView" service at

https://portfolio.shareview.co.uk/. You can contact SLC Registrars for assistance with the process at office@slcregistrars.com

or on +44 (0)20 3890 2122. There is no charge for this service. Akari encourages you to agree to the use of electronic communications

as it will enable you to receive information quicker and reduce the Company's costs and environmental impact.

A copy of the Statutory

Accounts can be accessed by visiting the Akari website at http://investor.akaritx.com/.

Your vote is important.

The affirmative vote (on a show of hands or a poll) of shareholders present in person or by proxy in accordance with the requisite majority

set forth in the accompanying Proxy Statement is required for approval of the Resolutions. We encourage you to read the Proxy Statement

Please complete, date,

sign and return the enclosed proxy form as promptly as possible (and in any event by 2.30 p.m. (London time) on June 28,

2022) in order to ensure your representation at the Meeting. Please note, however, that if your shares are represented by American Depositary

Shares and held on deposit by Deutsche Bank Trust Company Americas, as depositary, or if your ordinary shares are held of record by a

broker, bank or other nominee, and you wish to have your votes cast at the Meeting, you must obtain, complete and timely return a proxy

form issued in your name from that intermediary in accordance with any instructions provided therewith.

THE AKARI BOARD OF DIRECTORS HAS DETERMINED

AND BELIEVES THAT EACH OF THE RESOLUTIONS OUTLINED ABOVE IS ADVISABLE TO, AND IN THE BEST INTERESTS OF, AKARI AND ITS SHAREHOLDERS AND

HAS APPROVED EACH SUCH RESOLUTION. THE AKARI BOARD OF DIRECTORS RECOMMENDS THAT AKARI SHAREHOLDERS VOTE "FOR" EACH SUCH RESOLUTION.

2022 ANNUAL GENERAL MEETING OF SHAREHOLDERS

TO BE HELD ON JUNE 30, 2022

This Proxy Statement is furnished

in connection with the solicitation of proxies by the Board of Directors (the "Board") of Akari Therapeutics,

Plc, a public limited company registered in England & Wales ("Akari", the "Company"

or "our"), for use at the Company's 2022 Annual General Meeting (the "Meeting")

of shareholders to be held at 75/76 Wimpole Street, London, W1G 9RT on June 30, 2022, at 2.30 p.m. local time for the purpose

of considering and, if thought fit, passing the resolutions specified in the Notice of Annual General Meeting. This Proxy Statement is

being mailed to shareholders on or about June 6, 2022.

For a proxy form to be effective,

it must be properly executed and dated and lodged (together with a duly signed and dated power of attorney or other authority (if any)

under which it is executed (or a notarially certified copy of such power of attorney or other authority)) at the offices of the Company's

registrars, SLC Registrars (the "Registrars") at PO Box 5222, Lancing, BN99 9FG, United Kingdom (or by email

to proxy@slcregistrars.com) so as to be received by 2.30 p.m. local time on June 28, 2022 (or, if the Meeting is adjourned,

not less than 48 hours before the time of the adjourned Meeting). Each proxy form properly tendered appointing the Chairman of the Meeting

will, unless otherwise directed by the shareholder, be voted FOR the proposals subject to a binding vote, FOR the nominees described in

this Proxy Statement and at the discretion of the proxy holder with regard to all other matters that may properly come before the Meeting.

The Company will pay all of

the costs of soliciting proxies. We will provide copies of our proxy materials to the depositary for our American Depositary Shares (Deutsche

Bank Trust Company Americas), brokerage firms, fiduciaries and custodians for forwarding to beneficial owners and will reimburse these

persons for their costs of forwarding these materials. Our directors, officers and employees may also solicit proxies; however, we will

not pay them additional compensation for any of these services. Proxies may be solicited by telephone, facsimile, or personal solicitation.

Special Arrangements for Attendance in the

Although there are currently

no UK Government restrictions on travel or public gatherings in connection with Covid-19, it remains possible that such restrictions or

other impediments may make it difficult or impossible for shareholders, or their proxies other than the chairman of the Meeting, to attend

the Meeting in person. Shareholders should inform themselves of and comply with all laws and UK Government guidance in force at the date

of the Meeting. Moreover, for their own safety and that of our staff and the public, we encourage shareholders not to attend the Meeting

in person unless they have a good reason for doing so. We therefore strongly encourage you to vote on all resolutions as soon as possible

by appointing the chairman of the Meeting as your proxy (or, in the case of beneficial owners who hold their shares indirectly, by submitting

appropriate proxy voting instructions) as described in this Proxy Statement.

We expect only the Chairman

and a very limited number of Company personnel to be in attendance at the Meeting in person to ensure a quorum. We expect our Chief Executive

Officer to participate by video link. Social distancing and other appropriate health and safety measures will be in place in order to

comply with the law and Government guidelines and maximize the safety and comfort of those in attendance. Shareholders can submit questions

to the Board by email to the Company's investor relations department at peter.vozzo@westwicke.com by no later than June 28,

2022. We will consider all questions received and, if appropriate, provide a written response on the Company's website (http://investor.akaritx.com/).

The Board will keep the situation under review and may make changes to the arrangements for the Meeting, should the Covid-19 situation,

applicable laws or the UK Government's guidance change. Shareholders should therefore monitor the Company's website and announcements

Shares Outstanding and Voting Rights